Publications
Specialty
Search
Cath Lab Digest, Journal of Invasive Cardiology, CardioVascular
10/28/2024
High-intensity focused ultrasound waves micro-fracture calcification embedded in aortic valve leaflets without damaging tissue. The treatment is designed to be repeatable over time, as needed, to manage disease progression.
Wounds, Wound Care
10/28/2024
Frank & Lizzie interview Martin Burns, CEO of Bruin Biometrics LIVE, from the SAWC Fall studio in Las Vegas. Martin shares with the audience what the Provizio® SEM Scanner is, the wealth of evidence behind it, and how it’s used in daily practice to improve outcomes in our patients. The latest clinical evidence highlights the conservation of clinician hours and interventions, how this product can address dark skin tones, and how it can take the mystery out of the understanding the increased risk of pressure injuries earlier than visual and tactile assessments.
Advances in Inflammatory Bowel Disease Network
10/28/2024
Dr Regueiro reports from the ACG Scientific Meeting that a study of Janus kinase (JAK) inhibitors for treatment of ulcerative colitis and Crohn's disease provided reassurance of the safety of these small molecules.
Cath Lab Digest, Journal of Invasive Cardiology, Vascular Disease Management, CardioVascular
10/28/2024
The BASHIR™ Endovascular Catheter was used to deliver 4mg of recombinant tissue plasminogen activator (r-tPA) into each pulmonary artery (PA). The study showed that the independent core laboratory assessed primary endpoint of the right ventricular to left ventricular (RV/LV) diameter ratio at 48 hours was reduced by 22.3% (p=0.0001).
Cath Lab Digest, Journal of Invasive Cardiology, CardioVascular
10/28/2024
With a median follow up of 3.8 years, the data demonstrated superiority of early TAVR, with 26.8% of the 455 patients in the TAVR arm experiencing death, stroke or unplanned cardiovascular hospitalization compared to 45.3% of the 446 patients in the clinical surveillance arm.
EP Lab Digest, Cath Lab Digest, Vascular Disease Management, CardioVascular
10/28/2024
HMP Global, in partnership with Occupational Radiation Safety in Interventional Fluoroscopy (ORSIF), will host the first-of-its-kind Global Symposium on Interventional Radiation Protection (SIRP), to be held September 26-27, 2025.
Neurology
10/28/2024
Elivaldogene autotemcel (eli-cel) gene therapy for cerebral adrenoleukodystrophy (CALD) helped patients maintain neurological function, but also my have caused hematologic malignancies in some patients.
Lymphoma, Leukemia & Myeloma Network, Oncology
10/28/2024
At the 2024 Lymphoma, Leukemia & Myeloma Congress, Mark Bustoros, MD, shares expert insight into the unmet clinical needs in targeting and treating patients with extramedullary multiple myeloma, an aggressive subtype of myeloma.
EMSWorld
10/28/2024
WyoFile journalist Madelyn Beck's series on Wyoming’s embattled EMS industry unpacks a notoriously underreported field. Learn more about the series from the writer herself.
APP Institute Oncology
10/28/2024
According to second interim data from the MARIPOSA-2 trial, amivantamab plus chemotherapy numerically improved the overall survival, and significantly prolonged the post-progression outcomes among patients with EGFR-mutant non-small cell lung cancer.
APP Institute Oncology
10/28/2024
According to results from the phase 2b REZILIENT1 study, zipalertinib demonstrated promising anti-tumor activity among patients with EGFR exon 20 insertion-mutated non-small cell lung cancer who experienced disease progression after treatment with amivantamab.
APP Institute Oncology
10/28/2024
A novel EGFR x HER3 bispecific ADC showed encouraging antitumor activity for heavily-pretreated advanced urothelial carcinoma.
APP Institute Oncology
10/28/2024
Benjamin Besse, MD, PhD, discusses early analysis results from the MARIPOSA study which demonstrated that amivantamab plus lazertinib has promising antitumor activity in patients with advanced EGFR-mutated NSCLC.
Cath Lab Digest, Journal of Invasive Cardiology, CardioVascular, EP Lab Digest
10/28/2024
The pivotal investigational device exemption (IDE) study, which enrolled 256 patients at 18 sites in the US, met the primary endpoint. MACCE (Major Adverse Cardiac and Cerebrovascular Events) rate at 30 days was 6.3%, significantly below the pre-defined performance goal (see figure 1).
Vascular Disease Management, CardioVascular, Journal of Invasive Cardiology
10/28/2024
First-of-its-kind Dual-Drug Therapy for Coronary De Novo Disease Moves Toward U.S. Clinical Phase
Podiatry Today, Podiatry
10/28/2024
Podiatry Today spoke to Nicholas R. Butler, DPM, AACFAS, FACPM, FASPS, about his ASPS presentation on the evolution of the Lapidus arthrodesis.
Cath Lab Digest, Journal of Invasive Cardiology, CardioVascular
10/28/2024
The investigators shared the first randomized controlled trial (RCT) of FFRangio outcomes compared to invasive wire-based fractional flow reserve (FFR) has met its primary endpoint and revealed significant economic and resource utilization advantages for the non-invasive FFRangio technology over traditional wire-based approaches.
Psych Congress Network
10/28/2024
Christoph Correll, MD, offers clinical guidance for managing adverse affects from schizophrenia treatment, including weight gain and movement disorder
Cath Lab Digest, Journal of Invasive Cardiology, CardioVascular
10/28/2024
The Armery solution maximizes support and protection during radial procedures, and furthers Rampart’s mission to provide radiation protection solutions for healthcare teams delivering care in interventional suites.
Cath Lab Digest, Journal of Invasive Cardiology, CardioVascular
10/27/2024
The A-FLUX Reducer System is engineered with SwiftCell Technology™, a small-cell proprietary design based on computational modeling, to redistribute oxygen supply to the sub-endocardium layer of the heart muscle.
Reimbursement Library From A to Z
Subscribe and never miss an article!
Today's Wound Clinic Newsletter
